Published on 27 Mar 2023 on The Business Journals
Gaithersburg’s Novavax locks in consulting deal with outgoing R&D head - Washington Business Journal
Novavax's longtime research and development head is moving forward with plans to retire. That and...
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline
The market expects Provention Bio, Inc. (PRVB) to deliver a year-over-year decline in earnings on...
Provention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimates
Provention Bio, Inc. (NASDAQ:PRVB) just released its latest full-year results and things are look...
12 Most Promising Healthcare Stocks According to Analysts
In this article, we will take a look at the 12 most promising healthcare stocks according to anal...
Diabetes drug developer Biomea Fusion seeks $125 million - San Francisco Business Times
Strong diabetes drug trial pushes $BMEA to target $125 million stock sale
Gaithersburg’s Novavax locks in consulting deal with outgoing R&D head - Washington Business Journal
Novavax's longtime research and development head is moving forward with plans to retire. That and...
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
(Reuters) -Sanofi's asthma drug Dupixent met all targets in a trial to treat "smoker's lung",...
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Call Transcript
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Good af...
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
Shares of Provention Bio PRVB were up 260% on Mar 13 after the company announced that it has sign...
Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal
By Ludwig Burger and Dina Kartit (Reuters) -France's Sanofi SA on Monday agreed to acquire ...
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Sanofi SA (NASDAQ: SNY) has agreed to acquire Provention Bio Inc (NASDAQ: PRVB) for $25.00 per sh...